Idogen AB (OSTO:IDOGEN) Total Liabilities: kr3.09 Mil (As of Mar. 2023)


OSTO:IDOGEN Idogen AB OSTO:IDOGEN
21 GF Score
Price kr0.12
View Full Analysis

What is Idogen AB Total Liabilities?

Idogen AB OSTO:IDOGEN 21 Total Liabilities is kr3.09 Mil as of Mar. 2023. GuruFocus rates OSTO:IDOGEN with a GF Score™ of 21/100.

Idogen AB's Total Liabilities for the quarter that ended in Mar. 2023 was kr3.09 Mil.

Idogen AB's quarterly Total Liabilities declined from Sep. 2022 (kr6.25 Mil) to Dec. 2022 (kr5.38 Mil) and declined from Dec. 2022 (kr5.38 Mil) to Mar. 2023 (kr3.09 Mil).

Idogen AB's annual Total Liabilities increased from Dec. 2020 (kr10.22 Mil) to Dec. 2021 (kr12.08 Mil) but then declined from Dec. 2021 (kr12.08 Mil) to Dec. 2022 (kr5.38 Mil).

Idogen AB Total Liabilities Historical Data

* Premium members only.

The historical data trend for Idogen AB's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Idogen AB Total Liabilities Chart

Idogen AB Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Total Liabilities
Get a 7-Day Free Trial Premium Member Only 20.65 12.86 10.22 12.08 5.38

Idogen AB Quarterly Data
Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.64 5.71 6.25 5.38 3.09
OSTO:IDOGEN
21GF Score
Idogen AB OSTO:IDOGEN
Total Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Idogen AB Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Idogen AB's Total Liabilities for the fiscal year that ended in Dec. 2022 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=5.384+(0+0
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=5.38

Total Liabilities=Total Assets (A: Dec. 2022 )-Total Equity (A: Dec. 2022 )
=8.996-3.612
=5.38

Idogen AB's Total Liabilities for the quarter that ended in Mar. 2023 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=3.086+(0+0
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=3.09

Total Liabilities=Total Assets (Q: Mar. 2023 )-Total Equity (Q: Mar. 2023 )
=5.119-2.033
=3.09

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Liabilities →
What does a Total Liabilities of kr3.09 Mil mean?
Idogen AB (OSTO:IDOGEN) has a Total Liabilities of kr3.09 Mil as of Mar. 2023. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Idogen AB and its competitors.
Is Idogen AB's Total Liabilities too high?
Idogen AB's current Total Liabilities is kr3.09 Mil. Overall, Idogen AB has a GF Score™ of 21/100, reflecting its overall financial health beyond just this single metric.
How does Idogen AB's Total Liabilities compare to REGN and VRTX?
Idogen AB's Total Liabilities of kr3.09 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Liabilities for a Biotechnology company?
A good Total Liabilities depends on the Biotechnology industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Liabilities mean?
A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Idogen AB and its competitors. Idogen AB's current Total Liabilities is kr3.09 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Idogen AB stock overvalued right now?
Idogen AB (OSTO:IDOGEN) has a current Total Liabilities of kr3.09 Mil. The current Total Liabilities is kr3.09 Mil. Idogen AB's overall GF Score™ is 21/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Liabilities calculated?
Total Liabilities is calculated from a company's financial statements. For Idogen AB (OSTO:IDOGEN), the current Total Liabilities is kr3.09 Mil as of Mar. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Idogen AB Business Description

Address Medicon Village, Scheelevagen 2, Lund, SWE, 223 81
Idogen AB is a Swedish biotech company engaged in developing tolerogenic cell therapies to prevent biological drugs, transplanted or body cells or tissues from being attacked by the patient's immune system. Its product IDO 8, treats patients with severe hemorrhagic disease.
21GF Score

Get the complete analysis for OSTO:IDOGEN

Total Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr0.12
Price